Anesthesia and analgesia
-
Anesthesia and analgesia · Nov 1999
Randomized Controlled Trial Comparative Study Clinical TrialVisual estimation of onset time at the orbicularis oculi after five muscle relaxants: application to clinical monitoring of tracheal intubation.
The onset time of neuromuscular blockade at the adductor pollicis (AP) is different among neuromuscular blocking drugs, but these discrepancies had never been studied at the orbicularis oculi (OO). The purpose of this study was to verify if the differences in onset time observed at the AP still existed at the OO and to score the intubating conditions using monitoring at the OO after five muscle relaxants. The study included 172 adults aged 18-75 yr. Anesthesia was induced with fentanyl and propofol. Atracurium (0.5 mg/kg), mivacurium (0.20 mg/kg), rocuronium (0.6 mg/kg), succinylcholine (1.0 mg/kg), or vecuronium (0.08 mg/kg) was injected by random allocation. Time to complete disappearance of the response at the OO was assessed visually after train-of-four stimulation of the facial nerve. Laryngoscopy was then performed, and intubating conditions were determined on a scale of 1-4. Results were based on 150 patients. Onset time at the OO was (mean +/- SD): succinylcholine (57 +/- 17 s) < mivacurium (99 +/-19 s) = rocuronium (99 +/- 47 s) < atracurium (129 +/-33 s) = vecuronium (135 +/- 38 s) (P < 0.05). Overall intubating conditions were excellent (84%), good (14%), poor (1.3%), impossible (0.7%), and were similar among the five groups. We conclude that differences in onset time of muscle relaxants observed at the AP were also found at the OO. Visual estimation of the response at the OO correctly predicted good-to-excellent intubating conditions in more than 90% of cases for all the currently available muscle relaxants. ⋯ Onset time of neuromuscular blockade, as estimated visually at the orbicularis oculi, depends on the muscle relaxants given. Regardless of the relaxant used, intubating conditions at loss of orbicularis oculi are acceptable.
-
Anesthesia and analgesia · Nov 1999
Randomized Controlled Trial Comparative Study Clinical TrialPressures exerted against the cervical vertebrae by the standard and intubating laryngeal mask airways: a randomized, controlled, cross-over study in fresh cadavers.
In this randomized, controlled, cross-over study, we measured the pressures exerted by the standard laryngeal mask airway (LMA) and the intubating laryngeal mask airway (ILM) against the cervical vertebrae during insertion, intubation, and maneuvers commonly used to facilitate intubation. We also assessed the effect of these pressures on cervical spine (C-spine) movement. Twenty cadavers (6-24 h postmortem) without cervical abnormality were initially studied. Three microchip pressure sensors were implanted into the pharyngeal surface of C2-3. The size 5 ILM and LMA were inserted in random order into each cadaver with the head-neck in the neutral position. Maximal cervical pressures (CPmax) were recorded for both devices during cuff inflation from 0-40 mL and with the intracuff pressure (ICP) at 60 cm H2O, insertion, fiberscope-guided intubation, partial withdrawal/reinsertion (ILM only), elevation/depression of the handle with 20 N of force applied (ILM only). In five additional matched cadavers, the effect of pressure on posterior displacement of C3 was assessed, and CPmax was measured during laryngoscope- and fiberscope-guided oro/nasotracheal intubation (controls). CPmax was higher for the ILM than the LMA over the inflation range (96 vs 15 cm H2O; P < 0.0001) and with the ICP at 60 cm H2O (95 vs 10 cm H2O; P < 0.0001). During cuff inflation, CPmax was generally unchanged for the ILM but was always increased for the LMA. CPmax for the LMA and ILM was similar during insertion (224 vs 273 cm H2O) but higher for the ILM during fiberscope-guided intubation (96 vs 43 cm H2O; P < 0.0001). At 60 cm H2O ICP, CPmax increased during LMA (224 cm H2O; P < 0.0001) and ILM insertion (273 cm H2O; P < 0.0001) and increased for the LMA (43 cm H2O; P < 0.0001) but was unchanged for the ILM (96 cm H2O) during fiberscope-guided intubation. For the ILM, CP-max increased during handle depression (394 cm H2O; P < 0.0001) and partial withdrawal/reinsertion (265 cm H2O; P < 0.0001) but decreased during handle elevation (6 cm H2O; P < 0.00001). CPmax for the controls was usually zero and was always less than the LMA/ ILM (P < 0.0001). The mean (range) for posterior displacement of C3 was 0.8 (0-2) mm at 100 cm H2O and 2.8 (1-5) mm at 400 cm H2O. Laryngeal mask devices exert greater pressures against the cervical vertebrae than established intubation techniques and can produce posterior displacement of the C-spine. ⋯ Laryngeal mask devices exert greater pressures against the cervical vertebrae than established intubation techniques and can produce posterior displacement of the cervical spine. We recommend that laryngeal mask devices only be used in the unstable cervical spine if difficulties are anticipated or encountered with established techniques, pending the results of studies demonstrating its relative safety.
-
Anesthesia and analgesia · Nov 1999
Cerebral response to hemodilution during hypothermic cardiopulmonary bypass in adults.
We examined the cerebral response to changing hematocrit during hypothermic cardiopulmonary bypass (CPB) in 18 adults. Cerebral blood flow (CBF), cerebral metabolic rate for oxygen (CMRO2), and cerebral oxygen delivery (CDO2) were determined using the nitrous oxide saturation technique. Measurements were obtained before CPB at 36 degrees C, and twice during 27 degrees C CPB: first with a hemoglobin (Hgb) of 6.2 +/- 1.2 g/dL and then with a Hgb of 8.5 +/- 1.2 g/dL. During hypothermia, appropriate reductions in CMRO2 were demonstrated, but hemodilution-associated increases in CBF offset the reduction in CBF seen with hypothermia. At 27 degrees C CPB, as the Hgb concentration was increased from 6.2 to 8.5 g/ dL, CBF decreased. CDO2 and CMRO2 were no different whether the Hgb was 6.2 or 8.5 g/dL. In eight patients in whom the Hgb was less than 6 g/dL, CDO2 remained more than twice CMRO2. ⋯ This study suggests that cerebral oxygen balance during cardiopulmonary bypass is well maintained at more pronounced levels of hemodilution than are typically practiced, because changes in cerebral blood flow compensate for changes in hemoglobin concentration.
-
Anesthesia and analgesia · Nov 1999
Randomized Controlled Trial Multicenter Study Clinical TrialThe potency (ED50) and cardiovascular effects of rapacuronium (Org 9487) during narcotic-nitrous oxide-propofol anesthesia in neonates, infants, and children.
We studied the neuromuscular blocking effects of rapacuronium (Org 9487) (dose-response curve, onset, and 50% effective dose [ED50] value), and changes in heart rate and blood pressure, as well as evidence of histamine release in neonates, infants, and children in an open-label, randomized, two-center study. Fifteen neonates, 30 infants, and 30 children were studied. Anesthesia was induced and maintained with propofol, nitrous oxide:oxygen (60:40), and fentanyl. Mechanomyographic monitoring of neuromuscular function was performed at the thumb. The potency (ED50) for neonates, infants, and children were 0.32 (95% confidence interval [CI] 0.15-0.61), 0.28 (95% CI 0.11-0.61), and 0.39 (95% CI 0.17-0.85) mg/kg, respectively. Neonates who received 0.3, 0.6, or 0.9 mg/kg Org 9487 developed a maximum T1 twitch depression of 34 +/-28%, 98 +/- 3%, and 99 +/- 2%, respectively. Time-to-peak effect (onset time) for 0.9 mg/kg Org 9487 was 57 +/- 20 s. Maximum percent T1 twitch depression (+/-SD) in infants who received 0.3, 0.6, or 0.9 mg/kg rapacuronium was 41 +/- 34%, 96 +/- 7%, and 100 +/- 1%, respectively. Time-to-peak effect for 0.9 mg/kg Org 9487 was 62 +/- 29 s. In children 0.3, 0.6, and 0.9 mg/kg rapacuronium resulted in an average percent T1 twitch suppression of 29 +/- 23, 83 +/- 11, and 90 +/- 16, respectively. Time-to-peak effect of 0.9 mg/kg Org 9487 was 96 +/- 33 s, respectively. There was no evidence of histamine release or significant changes in heart rate or blood pressure in either group at any dose. Rapacuronium is a low-potency nondepolarizing muscle relaxant with a fast onset of relaxation and minimal cardiovascular effects. Its potency (ED50) is similar in neonates (0.32 mg/kg), infants (0.28 mg/kg), and children (0.39 mg/kg). T1 suppression (90% +/- 16) is less and time to peak effect (96 +/- 33 s) is greater (0.9 mg/kg rapacuronium) in children, compared with the combined group of infants and neonates. ⋯ This study assesses the potency of rapacuronium (Org 9487) in pediatric patients. The potency of rapacuronium is similar in neonates (0.32 mg/kg), infants (0.28 mg/kg), and children (0.39 mg/kg).